BioCardia, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $0 | $58,000 | $477,000 | $1.4M | $1.0M |
| Cost of revenue | — | — | — | — | $0 |
| Selling, general & administrative | $3.3M | $3.7M | $4.4M | $4.4M | $5.1M |
| Research and development | $5.0M | $4.4M | $7.7M | $8.8M | $8.6M |
| Operating income | -$8.3M | -$8.0M | -$11.6M | -$11.9M | -$12.6M |
| Interest expense | — | — | — | — | $0 |
| Income tax expense | $0 | $0 | $0 | $0 | $0 |
| Net income | -$8.2M | -$7.9M | -$11.6M | -$11.9M | -$12.6M |
| Balance Sheet | |||||
| Cash and equivalents | $2.5M | $2.4M | $1.1M | $7.4M | $12.9M |
| Current assets | $2.7M | $2.6M | $1.5M | $7.9M | $13.5M |
| Total assets | $3.4M | $3.7M | $3.0M | $9.8M | $15.7M |
| Current liabilities | $2.4M | $2.3M | $3.6M | $3.6M | $3.7M |
| Total liabilities | $2.5M | $2.9M | $4.6M | $4.9M | $5.3M |
| Stockholders' equity | $895,000 | $837,000 | -$1.6M | $4.9M | $10.4M |
| Cash Flow Statement | |||||
| Cash from operations | -$7.4M | -$7.9M | -$10.0M | -$10.6M | -$10.4M |
| Depreciation and amortization | $24,000 | $67,000 | $84,000 | $82,000 | $60,000 |
| Stock-based compensation | $430,000 | $741,000 | $1.0M | $1.2M | $1.7M |
| Capital expenditure | $7,000 | $6,000 | $12,000 | $70,000 | $116,000 |
| Free cash flow | -$7.4M | -$7.9M | -$10.0M | -$10.6M | -$10.5M |
| Impairments | — | — | — | — | $0 |
Shares outstanding 11.4M · Free float 81.5%
Annual filing data through FY ended December 31, 2025; float as of July 11, 2026.